Patents by Inventor Teerapong Yata
Teerapong Yata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230265452Abstract: The invention provides hybrid and recombinant phagemid vectors for expressing a transgene in a target cell transduced with the vector. A recombinant phagemid particle comprises at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome. The invention extends to the use of such phagemid expression systems as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques. The invention extends to in vitro, in vivo or in situ methods for producing viral vectors, such as recombinant adeno-associated viruses (rAAV) or lentivirus vectors (rLV), and to genetic constructs used in such methods.Type: ApplicationFiled: September 29, 2022Publication date: August 24, 2023Applicant: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Amin Hajitou, Paladd Asavarut, Teerapong Yata
-
Patent number: 11603540Abstract: The invention provides hybrid and recombinant phagemid vectors for expressing a transgene in a target cell transduced with the vector. A recombinant phagemid particle comprises at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome. The invention extends to the use of such phagemid expression systems as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques. The invention extends to in vitro, in vivo or in situ methods for producing viral vectors, such as recombinant adeno-associated viruses (rAAV) or lentivirus vectors (rLV), and to genetic constructs used in such methods.Type: GrantFiled: October 31, 2016Date of Patent: March 14, 2023Assignee: Imperial College Innovations LimitedInventors: Amin Hajitou, Paladd Asavarut, Teerapong Yata
-
Patent number: 10799542Abstract: The invention provides a recombinant targeted bacteriophage for expressing a transgene in a target cell transduced with the bacteriophage. The bacteriophage comprises a first nucleic acid sequence encoding a pill capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the bacteriophage to a target cell, a second nucleic acid sequence encoding at least one pVIII capsid major coat protein that is configured to display a foreign peptide thereon, and a transgene which encodes a protein which exerts a biological effect on the target cell.Type: GrantFiled: May 12, 2014Date of Patent: October 13, 2020Assignee: Imperial College Innovations LimitedInventors: Amin Hajitou, Teerapong Yata
-
Patent number: 10471138Abstract: The invention provides a targeted bacteriophage-polymer complex comprising a recombinant targeted-bacteriophage and a cationic polymer. The complex has a net positive charge. The invention provides methods of preparing bacteriophages and complexes thereof, and to their uses for the delivery of transgenes in a variety of gene therapy applications.Type: GrantFiled: September 19, 2018Date of Patent: November 12, 2019Assignee: Imperial College Innovations LimitedInventors: Amin Hajitou, Teerapong Yata
-
Publication number: 20190083610Abstract: The invention provides a targeted bacteriophage-polymer complex comprising a recombinant targeted-bacteriophage and a cationic polymer. The complex has a net positive charge. The invention provides methods of preparing bacteriophages and complexes thereof, and to their uses for the delivery of transgenes in a variety of gene therapy applications.Type: ApplicationFiled: September 19, 2018Publication date: March 21, 2019Applicant: Imperial Innovations LimitedInventors: Amin Hajitou, Teerapong Yata
-
Publication number: 20180320200Abstract: The invention provides hybrid and recombinant phagemid vectors for expressing a transgene in a target cell transduced with the vector. A recombinant phagemid particle comprises at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome. The invention extends to the use of such phagemid expression systems as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques. The invention extends to in vitro, in vivo or in situ methods for producing viral vectors, such as recombinant adeno-associated viruses (rAAV) or lentivirus vectors (rLV), and to genetic constructs used in such methods.Type: ApplicationFiled: October 31, 2016Publication date: November 8, 2018Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Amin Hajitou, Paladd Asavarut, Teerapong Yata
-
Publication number: 20170340684Abstract: The invention provides a recombinant targeted bacteriophage for expressing a transgene in a target cell transduced with the bacteriophage. The bacteriophage comprises a first nucleic acid sequence encoding a pill capsid minor coat protein that is configured to display a cell-targeting ligand for enabling delivery of the bacteriophage to a target cell, a second nucleic acid sequence encoding at least one pVIII capsid major coat protein that is configured to display a foreign peptide thereon, and a transgene which encodes a protein which exerts a biological effect on the target cell.Type: ApplicationFiled: May 12, 2014Publication date: November 30, 2017Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Amin Hajitou, Teerapong Yata
-
Publication number: 20160114032Abstract: The invention provides a targeted bacteriophage-polymer complex comprising a recombinant targeted-bacteriophage and a cationic polymer. The complex has a net positive charge. The invention provides methods of preparing bacteriophages and complexes thereof, and to their uses for the delivery of transgenes in a variety of gene therapy applications.Type: ApplicationFiled: May 12, 2014Publication date: April 28, 2016Applicant: Imperial Innovations LimitedInventors: Amin Hajitou, Teerapong Yata